Tibet Rhodiola Pharmaceutical's Xin Hu Su secures national medical insurance inclusion

On December 7, 2025, Tibet Rhodiola Pharmaceutical Holding announced that its product, Recombinant Human Brain Natriuretic Peptide for Injection (brand name: Xin Hu Su), will continue to be part of the national medical insurance drug catalog. Previously under Class B, Xin Hu Su has been reclassified to the regular directory, with the change taking effect from January 1, 2026. This classification limits its use to Grade II and above medical institutions for the short-term treatment of acute decompensated heart failure with poor treatment outcomes, with a maximum three-day payment for hospital stays.

Xin Hu Su, an independently developed Class 1 biological new drug, is a significant revenue driver for the company. In 2024, it generated revenue of 2.433 billion yuan, accounting for 86.89% of the company's main business income. For the first half of 2025, revenue totaled 1.456 billion yuan, representing 88.36% of main business income.

The company anticipates that this continued inclusion and reclassification will positively impact future product sales and long-term development, though the specific financial impact on operating performance cannot yet be estimated.